Roberto Zarrabeitia

Dr. Roberto Zarrabeitia


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
OVOn Behalf Of Vascern-Hht
On Behalf Of Vascern-Hht
EBElisabetta Buscarini
Elisabetta Buscarini
Luisa L BotellaLuisa L Botella
Luisa L Botella
UGUrban Geisthoff
Urban Geisthoff
AKAnette D. Kjeldsen
Anette D. Kjeldsen
CSClaire L. Shovlin
Claire L. Shovlin
Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT working group within the ERN for Rare Multisystemic Vascular Diseases (VASCERN), developed a questionnaire-based retrospective capture of adverse events (AEs) classified using the Common Terminology Criteria for Adverse Events. Sixty-nine HHT patients received bevacizumab, 37 (50.6%) for high output cardiac failure/hepatic AVMs, and 32 (49.4%) for bleeding; the 69 patients received bevacizumab for a mean of 11 months for a total of 63.8 person/years treatment. 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13.4 months/patient for a total of 75 person/years treatment. AEs were reported in 58 patients, 33 with bevacizumab, 37 with thalidomide. 32 grade 1–3 AEs related to bevacizumab were reported with an average incidence rate of 50 per 100 person-years. 34 grade 1–3 AEs related to thalidomide were reported with an average incidence rate of 45.3 per 100 person-years. Bevacizumab AEs were more common in females (27 AEs in 46 women) than males (6 in 23, p < 0.001). Thalidomide AEs occurred at more similar rates in males (25 AEs in 41 men, 60.9%) and females (12 in 26 (46.2%), but were more common in ENG patients (17 in 17) than in ACVRL1 (14 in 34, p < 0.0001). For bevacizumab, the most common reports were of joint pains (7/69, 10%), headache (3/69, 4.4%) and proteinuria (2/69, 3%), and for thalidomide, peripheral neuropathy (12/67, 18%); drowsiness (8/67, 12%); and dizziness (6/67, 9%). Fatal adverse events were more common in males (p = 0.009), and in patients with ENG pathogenic variants (p = 0.012). One fatal AE was possibly related to bevacizumab (average incidence rate: 1.5 per 100 person-years); 3 fatal AEs were possibly related to thalidomide (average incidence rate: 4 per 100 person-years). With potential increase in use of Bevacizumab and Thalidomide in HHT patients, data presented support appropriate weighing of the toxicities which can arise in HHT settings and the practice recommendations for their prevention and management.

23 January 2017 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
RZRoberto Zarrabeitia
Roberto Zarrabeitia
CFConcepción Fariñas-Álvarez
Concepción Fariñas-Álvarez
MSMiguel Santibáñez
Miguel Santibáñez
BSBlanca Señaris
Blanca Señaris
AFAna Fontalba
Ana Fontalba
JPJosé Antonio Parra
José Antonio Parra
There are very few studies about general quality of life parameters, standards for the description of health status and comparison with general population data on patients with Hereditary hemorrhagic telangiectasia (HHT), a rare disease in which epistaxis is a cardinal symptom. To assess the quality of life in a population of Spanish patients with HHT and compare it with the general population. Between January 1st 2005 and December 31st 2013, 187 adult patients diagnosed with HHT who were admitted to the HHT Unit of the Hospital Sierrallana, completed on their first visit, the EuroQol 5D-3L (five dimensions and three levels) quality of life descriptive test and the visual analog scale (VAS). The numerical social index value was also determined and the subjective effect of the nasal epistaxis on their quality of life was estimated classified as mild, moderate or severe. Patients with HHT had greater problems than the general population in the five dimensions of the EuroQol 5D-3L, particularly considering pain/discomfort and anxiety/depression. In the VAS and the social index value, patients with HHT also scored lower than the general population, particularly older patients, males, and patients with HHT2. They also had values similar to those of populations with chronic illnesses. The subjective perception of the severity of epistaxis correlated strongly with the VAS and social index values. The quality of life of patients with HHT, estimated using the EuroQol 5D-3L scale, is affected across all dimensions. The scores are similar to those seen in cases of other chronic diseases. Older patients, males and the carriers of the ACVRL1 mutation generally have worse scores on these scales. The VAS and the social index value are index that correlate well with the severity of the clinical symptoms associated mainly with epistaxis.

1 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ALAndreas Lux
Andreas Lux
RMRalf Müller
Ralf Müller
MTMark Tulk
Mark Tulk
COCarla Olivieri
Carla Olivieri
RZRoberto Zarrabeitia
Roberto Zarrabeitia
BWBernhard Wirnitzer
Bernhard Wirnitzer
The vascular disorder Hereditary Hemorrhagic Telangiectasia (HHT) is in general an inherited disease caused by mutations in the TGF-β/BMP receptors endoglin or ALK1 or in rare cases by mutations of the TGF-β signal transducer protein Smad4 leading to the combined syndrome of juvenile polyposis and HHT. HHT is characterized by several clinical symptoms like spontaneous and recurrent epistaxis, multiple telangiectases at sites like lips, oral cavity, fingers, nose, and visceral lesions like gastrointestinal telangiectasia, pulmonary, hepatic, cerebral or spinal arteriovenous malformations. The disease shows an inter- and intra-family variability in penetrance as well as symptoms from mild to life threatening. Penetrance is also depending on age. Diagnosis of the disease is based on the presence of some of the listed symptoms or by genetic testing. HHT diagnosis is laborious, time consuming, costly and sometimes uncertain. Not all typical symptoms may be present, especially at a younger age, and genetic testing does not always identify the disease causing mutation.

30 April 2007 in Acta Otorrinolaringológica Española
Verified
Journal Article
Closed access
CMCarmelo Morales Morales-Angulo
Carmelo Morales Morales-Angulo
AMAlfonso Pérez del Molino
Alfonso Pérez del Molino
RZRoberto Zarrabeitia
Roberto Zarrabeitia
ÁFÁfrica Fernández
África Fernández
FSFrancisco Sanz-Rodríguez
Francisco Sanz-Rodríguez
LBLuisa María Botella
Luisa María Botella

1 September 2016 in International Journal of Cardiology
Verified
Journal Article
Open access
JPJosé Antonio Parra
José Antonio Parra
JCJosé María Cuesta
José María Cuesta
RZRoberto Zarrabeitia
Roberto Zarrabeitia
CFConcepción Fariñas-Álvarez
Concepción Fariñas-Álvarez
JBJesús Bueno
Jesús Bueno
JZJesús Zarauza
Jesús Zarauza
Background and objectives: Because of the serious nature of potential complications, screening for pulmonary arteriovenous malformations is required in patients with hereditary hemorrhagic telangiectasia. The aim of this study was to evaluate the utility of contrast echocardiography and compare the performance of two contrast agents: agitated saline and Gelofusine. Material and methods: Two hundred and five patients screened for PAVMs using TTCE and computed tomography (CT) performed with an interval of less than 180 days. Contrast echocardiography studies were graded on a 4-point semiquantitative scale based on the amount of microbubbles seen in left heart chambers. Results: Positive TTCE findings were seen in 137 (66.8%) patients, whereas CT confirmed PAVMs in 59 (43.1%). Two of 67 grade 1 patients; 18 of 42 grade 2; 17 of 22 grade 3 and all grade 4 had PAVMs on CT. Embolotherapy was feasible in 38.9% patients in grade 2 and 82.3% and 95.2% in grades 3-4. No patients in grade 1 were embolized. The mean cardiac cycle in which bubbles were first seen in the left heart in patients without and with PAVMs on CT was 6.1 and 3.9 (p < 0.0001). Compared to saline, Gelofusine produced an overall increase in grade. Conclusions: No grade 1 patients had treatable PAVMs. There is a need for improvement in the selection of patients for CT in grade 2, where less than half have PAVMs on CT. The cardiac cycle may help to differentiate between patients with and without PAVMs. Gelofusine was not better than saline for PAVM screening. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

1 October 2010 in Medicina Clinica
Verified
Journal Article
Closed access
MVMiguel Angel Núñez Viejo
Miguel Angel Núñez Viejo
AMAna Fernández Montes
Ana Fernández Montes
José Luis HernándezJosé Luis Hernández
José Luis Hernández
FRFernando Pons Romero
Fernando Pons Romero
EGEmilio Fábrega García
Emilio Fábrega García
RZRoberto Zarrabeitia
Roberto Zarrabeitia